{"id":"W4280594357","doi":"10.1016/s2352-3026(22)00102-8","title":"Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"Novartis Pharmaceuticals Corporation; Novartis","keywords":"Ruxolitinib; Medicine; Polycythaemia; Clinical endpoint; Internal medicine; Phlebotomy; Myelofibrosis; Polycythemia vera; Clinical trial; Randomized controlled trial; Pediatrics; Surgery; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001802883,0.0003395127,0.002819989,0.0002426943,0.0002463966,0.00001271479,0.0003181986,0.0000792102,0.001597947],"category_scores_gemma":[0.0004583322,0.0002248593,0.0002355215,0.0003505892,0.0001536169,0.00004642136,0.000120748,0.0004726197,0.00009207233],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001796487,"about_ca_system_score_gemma":0.0003904515,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000486632,"about_ca_topic_score_gemma":0.0001838653,"domain_scores_codex":[0.9960715,0.00168312,0.0007735683,0.0004615861,0.0004328357,0.0005773871],"domain_scores_gemma":[0.996712,0.00198149,0.0003625394,0.000743754,0.00009227395,0.0001078986],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8673021,0.004748012,0.1179609,0.00003802914,0.00111947,0.001033691,0.003957473,0.00002623763,0.0005437927,0.001166043,0.001711629,0.0003926802],"study_design_scores_gemma":[0.9655591,0.01628012,0.004872672,0.00004816578,0.0005099179,0.0003856628,0.003841349,0.0002160135,0.002189918,0.0001110875,0.005705856,0.000280134],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9869192,0.001269163,0.000003132101,0.004084113,0.0004335608,0.004810391,0.0000817476,0.00004469843,0.002353969],"genre_scores_gemma":[0.995025,0.000322831,0.00007706755,0.0005435371,0.0001027518,0.00285422,0.00003309102,0.00004317455,0.0009982677],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1130882,"threshold_uncertainty_score":0.9993147,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08405562557028219,"score_gpt":0.35526130428884,"score_spread":0.2712056787185578,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}